|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net income (loss) | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Goodwill impairment | |||||
| Amortization of debt discount and deferred finance costs | |||||
| Change in fair value of investment in GMP Bio | |||||
| Deferred income taxes | |||||
| Stock compensation expense | |||||
| Loss on debt conversion | |||||
| Write off accounts receivable | |||||
| Change in fair value of derivative | |||||
| Changes in operating assets and liabilities: | |||||
| Prepaid expenses and other current assets | |||||
| Accounts payable and accrued expenses | |||||
| Accounts payable to related party | |||||
| Net cash used in operating activities | |||||
| Cash flows from financing activities: | |||||
| Proceeds from / (repayment to) private placement | |||||
| Proceeds from convertible debt | |||||
| Proceeds from short term loans, others | |||||
| Repaid to others | |||||
| Net cash provided by financing activities | |||||
| Net increase (decrease) in cash | |||||
| Cash and restricted cash - beginning of period | |||||
| Cash and restricted cash - end of period | |||||
| Supplemental cash flow information: | |||||
| Interest paid | |||||
| Income taxes paid | |||||
| Common shares issued upon partial conversion of debt | |||||
Loading...